PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: Placebo capsules
- First Posted Date
- 2007-09-19
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT00531752
- Locations
- πΊπΈ
Bay Area Research Institute, Lafayette, California, United States
πΊπΈPharmacology Research Institute, Newport Beach, California, United States
πΊπΈNew York University School of Medicine, New York, New York, United States
Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 459
- Registration Number
- NCT00531479
- Locations
- π¬π§
Pfizer Investigational Site, Manchester, United Kingdom
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
- Conditions
- Neoplasms
- Interventions
- Drug: Sunitinib, Pemetrexed, Cisplatin, Carboplatin
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 96
- Registration Number
- NCT00528619
- Locations
- π¨π¦
Pfizer Investigational Site, Montreal, Quebec, Canada
Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults
- Conditions
- AgingFrail Older Adults
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 396
- Registration Number
- NCT00527046
- Locations
- πΊπΈ
Pfizer Investigational Site, Seattle, Washington, United States
Multiple Dose, Dose Escalation Study of Varenicline Controlled Release Formulation in Adult Smokers
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2010-01-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT00527150
- Locations
- πΊπΈ
Pfizer Investigational Site, Fargo, North Dakota, United States
Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1
- Interventions
- Drug: CP-464,005
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00527397
- Locations
- π―π΅
Pfizer Investigational Site, Tokyo, Japan
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
- Conditions
- Influenza
- Interventions
- Biological: 13 valent pneumococcal conjugate vaccine
- First Posted Date
- 2007-08-28
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1116
- Registration Number
- NCT00521586
- Locations
- πΊπΈ
Accelovance, Peoria, Illinois, United States
πΊπΈFFM Clinical Research, Camillus, New York, United States
πΊπΈRochester Clinical Research, Rochester, New York, United States
Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2007-08-06
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 43
- Registration Number
- NCT00511849
- Locations
- πΊπΈ
Pfizer Investigational Site, Madison, Wisconsin, United States
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
- Conditions
- Hormone Refractory Prostate CancerProstate Cancer
- Interventions
- First Posted Date
- 2007-08-02
- Last Posted Date
- 2019-10-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 140
- Registration Number
- NCT00510718
- Locations
- πΊπΈ
Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States
πΊπΈInvestigational Pharmacy Services, Houston, Texas, United States
πΊπΈThe University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack
- Conditions
- Migraine
- First Posted Date
- 2007-08-02
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 73
- Registration Number
- NCT00510419
- Locations
- πΊπΈ
New England Center for Headache, Stamford, Connecticut, United States
πΊπΈDiamond Head Clinic, Chicago, Illinois, United States
πΊπΈClinvest, Springfield, Missouri, United States